This article is a correction to:
Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene
Jun Zhang
Zhijia Tang
Xi Guo2
Weimin Cai- 1Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China
- 2Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
By Zhang J, Tang Z, Guo X, Wang Y, Zhou Y and Cai W (2022) Front. Oncol. 12:933646. doi: 10.3389/fonc.2022.933646
In the published article, there were errors in Figures 2, 8 as published. In Figures 2A, B, we put the wrong representative plots in the previous Figure 2. Figures 8D, E showed the rates of migration and invasion with transfection for 24, 48, and 72 h. The third image in the second row of Figure 8E is the same as the one in the same position of Figure 8D. The image of cell invasion after transfection with Serpinc1-OE 48 h in Figure 8E was wrongly used. The corrected Figures 2, 8 are shown below.
FIGURE 2
Figure 2 Representative flow cytometric plots of MDSCs in (A) spleen (n = 3, biological duplicates), (B) tumor (n = 5, biological duplicates), and (C) peripheral blood (n = 3, biological duplicates) after treatment with nab-PTX and anti-PD-1 antibody.
FIGURE 8
Figure 8 Effects of Serpinc1 gene on cell migration, invasion, proliferation, and apoptosis. The transfection of Serpinc1 was determined using (A) Western blot analysis and (B) qRT-PCR by one-way ANOVA (n = 3). (C) Wound healing assay was measured and analyzed using two-way ANOVA (n = 3, magnification ×200). The rates of (D) migration and (E) invasion were determined with transfection for 24, 48, and 72 h with two-way ANOVA (n = 3, magnification ×400). (F) Colony formation assay (n = 3) and (G) CCK8 assay (n = 5) of Serpinc1 overexpressing LLC cells were used to determine cell viability with ANOVA. (H) Apoptotic cells post-transfection were detected on flow cytometry using one-way ANOVA (n = 6). *p< 0.05, ***p< 0.001, ****p< 0.0001. Serpinc1-OE, Serpinc1 overexpression.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: albumin-bound paclitaxel, combination drug therapy, lung cancer, PD-1, Serpinc1
Citation: Zhang J, Tang Z, Guo X, Wang Y, Zhou Y and Cai W (2023) Corrigendum: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the Serpinc1 gene. Front. Oncol. 13:1303608. doi: 10.3389/fonc.2023.1303608
Received: 28 September 2023; Accepted: 19 October 2023;
Published: 30 October 2023.
Edited and Reviewed by:
Tao Liu, University of New South Wales, AustraliaCopyright © 2023 Zhang, Tang, Guo, Wang, Zhou and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Weimin Cai, weimincai@fudan.edu.cn